Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : OrbiMed
Deal Size : $200.0 million
Deal Type : Series A Financing
Windward Bio Raises $200M to Advance Long-Acting Anti-TSLP Therapy
Details : The financing aims to advance the clinical development of WIN378 (HBM-9378), which is being evaluated for the treatment of severe asthma & chronic obstructive pulmonary disease.
Product Name : WIN378
Product Type : Antibody
Upfront Cash : Undisclosed
January 10, 2025
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : OrbiMed
Deal Size : $200.0 million
Deal Type : Series A Financing